文献速递关节外科

伯明翰髋关节表面置换植入物在美国的长期结果:单中心经验的更新分析

Long-Term Results of the Birmingham Hip Resurfacing Implant in the United States: An Updated Analysis of a Single Institution's Experience.
PubMed 文献 · J Bone Joint Surg Am · 2025-02-05

本研究更新报告单中心伯明翰髋关节表面置换(BHR)植入物的长期随访结果,共纳入224例患者(其中179例来自原研究),平均随访14年。15年免于任何翻修和免于无菌性翻修的生存率分别为96.0%和97.4%,患者报告结局与匹配的全髋关节置换(THA)患者相似。作者认为BHR植入物仍是年轻男性骨关节炎患者的优良选择。

要点

  • 15年免于任何翻修生存率96.0%,免于无菌性翻修生存率97.4%。
  • 血清钴和铬中位水平分别为1.4 ppb和1.5 ppb。
  • 患者报告结局与匹配的THA队列相似,BHR组保持高活动度的趋势更明显(p=0.12)。

核心结论

  • 作者认为,尽管长期随访时活动度与THA相似,BHR植入物仍是年轻男性骨关节炎患者的优良选择。

研究设计与样本

  • 单中心更新分析,共纳入224例具有当代适应症的患者,其中179例来自原研究,平均随访14年。
  • 生存率通过计算得出,金属离子水平和影像学检查做了更新,患者报告结局与匹配的THA患者进行比较。

主要发现

  • 15年免于任何翻修的生存率为96.0%,免于无菌性翻修的生存率为97.4%。
  • 自原研究以来有2例患者接受了翻修。
  • 血清钴和铬的中位水平分别为1.4 ppb和1.5 ppb。
  • 患者报告结局与THA队列相似。
  • 保持活动的患者比例两组相等,但BHR组保持高活动度的趋势更明显(p=0.12)。

关键数值与推荐

  • 15年免于任何翻修生存率96.0%,免于无菌性翻修生存率97.4%。
  • 血清钴中位水平1.4 ppb,铬中位水平1.5 ppb。
  • BHR组与THA组保持高活动度的比较p=0.12。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We previously reported the 5-year results of the Birmingham Hip Resurfacing (BHR) implant. This study evaluates BHR survivorship as well as radiographic and clinical outcomes at long-term follow-up. METHODS: A total of 224 patients with contemporary indications, including 179 patients from the original study, were included in this analysis. Survivorship was calculated. Metal ion levels and radiographs were updated. Patient-reported outcomes (PROs) were compared with those for matched patients who had undergone total hip arthroplasty (THA). The mean follow-up was 14 years. RESULTS: Survivorship free from any revision and from aseptic revision was 96.0% and 97.4% at 15 years, respectively. Two patients had undergone revision since the original study. The median serum cobalt and chromium levels were 1.4 and 1.5 ppb, respectively. The PROs were similar to those for the THA cohort. Equal proportions of patients remained active; however, the BHR group trended toward more remaining highly active (p = 0.12). CONCLUSIONS: Although activity was similar to THA at long-term follow-up, the BHR implant remains an excellent option for the treatment of osteoarthritis in younger male patients. LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Zuke WA, Hannon CP, Salih R, et al. Long-Term Results of the Birmingham Hip Resurfacing Implant in the United States: An Updated Analysis of a Single Institution's Experience. J Bone Joint Surg Am. 2025. PMID: 39908356. doi:10.2106/JBJS.24.00926

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。